Investigational drug · Phase 3
177Lu-edotreotide PRRT
Also called: 177Lu-DOTATOC, 177Lu-Edo, Peptide Receptor Radionuclide Therapy, 177Lu-DOTATOC 177Lu-Edo
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Neuroendocrine Tumors.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
15
Any phase or sponsor naming "177Lu-edotreotide PRRT"
First trial start
2017
Feb 2, 2017
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "177Lu-edotreotide PRRT", any sponsor or status.
Conditions studied
As listed on its trial records.
- Neuroendocrine Tumors
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "177Lu-edotreotide PRRT" as an intervention, largest first.
- Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET PatientsPivotal-lookingActive, not recruiting
ITM Solucin GmbHIndustry
NCT03049189 · 324 participants · Start Feb 2, 2017 · Primary completion Nov 27, 2024
Drug: 177Lu-edotreotide PRRT; Everolimus · For: Neuroendocrine Tumors
Sites: Gilbert, Arizona; Stanford, California; Tampa, Florida · 52 sites in all
- Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.Pivotal-lookingRecruiting
Lund University HospitalAcademic, hospital or other
NCT05387603 · 300 participants (planned) · Start Nov 1, 2022 · Primary completion Oct 1, 2026
Drug: 177Lu-DOTATOC; Capecitabine · For: Neuroendocrine Tumors
Sites: Gothenburg, Sweden; Lund, Sweden; Stockholm, Sweden · 4 sites in all
- Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSEPivotal-lookingActive, not recruiting
ITM Solucin GmbHIndustry
NCT04919226 · 259 participants · Start Dec 21, 2021 · Primary completion Jun 2027
Drug: 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT; CAPTEM (Capecitabine and Temozolomide) and 2 more · For: Neuroendocrine Tumors
Sites: Palo Alto, California; Aurora, Colorado; Tampa, Florida · 42 sites in all
- Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.Pivotal-lookingRecruiting
Grupo Espanol de Tumores NeuroendocrinosAcademic, hospital or other
NCT05918302 · 170 participants (planned) · Start Oct 27, 2023 · Primary completion Mar 2029
Drug: 177Lu-edotreotide; Everolimus · For: Neuroendocrine Tumors; Lung Neuroendocrine Neoplasm; Thymus Neoplasms
Sites: Edegem, Belgium; Brussels, Belgium; Liège, Belgium · 27 sites in all
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSAcademic, hospital or other
NCT06045260 · 100 participants (planned) · Start Sep 13, 2023 · Primary completion Feb 2025
Drug: 177Lu-DOTATOC · For: Neuroendocrine Tumors; Paraganglioma; Pheochromocytoma
Sites: Cesena, Italy; Meldola, Italy
- Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN PatientsPivotal-lookingRecruiting
Tine Gregersen, MDAcademic, hospital or other
NCT04917484 · 100 participants (planned) · Start Feb 1, 2020 · Primary completion Dec 2025
Drug: Lu-177-DOTA-Octreotide · For: Neuroendocrine Neoplasm
Sites: Aarhus, Denmark
IRCCS San RaffaeleAcademic, hospital or other
NCT04385992 · 31 participants · Start Mar 9, 2020 · Primary completion Jan 25, 2023
Drug: 177Lu-Dotatate · For: Neuroendocrine Tumors
Sites: Milan, Italy
- Personalized CAPTEM Radiopeptide Therapy of Advanced, Non-resectable Neuroendocrine CancerStatus unknown
University of Warmia and MazuryAcademic, hospital or other
NCT04194125 · 25 participants (planned) · Start Feb 1, 2019 · Primary completion Jun 30, 2021
Drug: 177Lu-DOTATOC · For: Neuroendocrine Tumors
Sites: Warsaw, Poland
University Hospital, Basel, SwitzerlandAcademic, hospital or other
NCT04997317 · 18 participants (planned) · Start Apr 21, 2021 · Primary completion Dec 31, 2026
Drug: 177Lu-DOTA-JR11 (Phase 0); Cycle 1 and Cycle 2 (cross-over); 177Lu-DOTATOC (Phase 0); Cycle 1 and Cycle 2 (cross-over), Cycle 3 and 4 and 1 more · For: Meningioma
Sites: Basel, Switzerland
University Hospital, Basel, SwitzerlandAcademic, hospital or other
NCT05359146 · 16 participants (planned) · Start Mar 28, 2023 · Primary completion Dec 2025
Drug: 161Tb-DOTA-LM3; 177Lu-DOTATOC · For: Neuroendocrine Neoplasia's (NENs); Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
Sites: Basel, Switzerland
Newest research
PubMed records naming it or its code names, newest first.
- Neuroendocrine Theranostics.
Kavanaugh M · Magn Reson Imaging Clin N Am 2027
- Hybrid Imaging in the Head and Neck: Focus on Somatostatin Receptor Imaging-DOTATATE is Great!
Kirsch CFE · Neuroimaging Clin N Am 2027
- Neuro-Oncology: Primary Brain Neoplasms.
Ward RE, Ivanidze J, Barajas RF, et al. · Neuroimaging Clin N Am 2027
- Radiopharmaceuticals for Melanoma Theranostics.
Meng C, Cheng Z, Ma X · Methods Mol Biol 2027
- Pediatric gigantism due to ectopic growth hormone releasing hormone secretion from a metastatic bronchial neuroendocrine tumor.
Vidal-Ostos De Lara F, Sanchis-Pascual D, Hernández-Rienda L, et al. · JCEM Case Rep 2026
- Prevention and management of hormonal crisis in neuroendocrine tumors undergoing PRRT (peptide receptor radionuclide therapy): a systematic review.
Arrivi G, Pagnanelli M, Puliani G, et al. · ESMO Gastrointest Oncol 2026
Also in development for Neuroendocrine Tumors
- Lutetium[177Lu] Oxodotreotidedotatate, 177Lu-DOTA0-Tyr3-OctreotatePhase 33 trials
Sinotau Pharmaceutical Group · Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma
- tirapazaminePhase 32 trials
Zhejiang Raygene Pharmaceuticals Co., Ltd · HCC, Hepatocellular Carcinoma, Gastrointestinal Cancer Metastatic
- CVM-1118TRX-818Phase 22 trials
TaiRx, Inc. · Hepatocellular Carcinoma, Advanced Cancer, Neuroendocrine Tumors
- CRN09682Phase 21 trial
Crinetics Pharmaceuticals Inc. · SST2-positive Neuroendocrine Neoplasms, Neuroendocrine Tumors, Neuroendocrine Neoplasm
- CTX-471Phase 21 trial
Compass Therapeutics · Neuroendocrine Neoplasm, Neuroendocrine Carcinomas, Neuroendocrine Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.